恩度联合热灌注治疗恶性腹腔积液的研究进展

Research Progress in Endostat Combined with Hyperthermic Perfusion in Treating Malignant Ascites

肿瘤晚期病人恶性腹腔积液(malignant ascites,MA)的形成原因是临床肿瘤学的一个关键问题,可能引起最严重的表现包括严重腹痛、恶病质、厌食和乏力等。近年来,不少研究者已在离体的恶性相关积液中找到了血管内皮生长因子(vascular endothelial growth factor,VEGF)高表达,虽无法确定VEGF是恶性积液的原因,但其拮抗物恩度(重组人血管内皮抑制素)在恶性腹腔积液治疗的发展前景乐观。近年来兴起的热灌注化疗技术,是对腹腔内罕见疾病的辅助治疗手段,化疗药物和热灌注治疗有协同效应,热效应有助于药物进入肿瘤细胞内发挥良好的杀伤效果。就恩度联合热灌注治疗恶性腹腔积液的有关研究成果和临床经验,并根据近期国内外的有关论文,对恩度联合热灌注治疗恶性腹腔积液(MA)的研究进行综述。

The formation reason of malignant ascites(MA)in patients with advanced cancer is a key issue in clinical oncology,which may cause the most serious manifestations,including severe abdominal pain,cachexia,anorexia,fatigue,etc.Many researchers have recently found high vascular endothelial growth factor(VEGF)expression in isolated malignant effusions.Although it can′t be determined whether VEGF is the cause of malignant effusions,its antagonist endostatin(recombinant human endostatin)has a promising development prospect in treating malignant ascites.The hyperthermic perfusion chemotherapy technology emerging in recent years is adjuvant therapy for rare intra abdominal diseases.The chemotherapeutic drugs and hyperthermic perfusion therapy have a synergistic effect,and the thermal effect helps the drugs enter the tumor cells and exert a good killing effect.This paper introduces the research results and clinical experience of Endostat combined with hyperthermic perfusion in treating malignant ascites,and reviews the research of Endostat combined with hyperthermic perfusion in treating malignant ascites based on recent domestic and foreign papers.